ZTS Q4 2023 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena

ZTSZoetis Inc.

$54B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.2B+8.5% YoY

Gross Profit

$1.4B65.4% margin

Operating Income

$709M32.0% margin

Net Income

$525M23.7% margin

EPS (Diluted)

$1.14

QoQ Revenue Growth

+2.9%

Cash Flow

Operating Cash Flow

$897M

Free Cash Flow

$699M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$14.3B

Total Liabilities

$9.3B

Stockholders' Equity

$5.0B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.2B	$2.0B	+8.5%
Gross Profit	$1.4B	$1.4B	+7.1%
Operating Income	$709M	$690M	+2.8%
Net Income	$525M	$461M	+13.9%

Revenue Segments

Horses

$5.1B87%

Cattle

$401M7%

Swine

$139M2%

Poultry

$127M2%

Fish

$62M1%

Geographic Segments

United States Segment

$1.2B55%

International Segment

$982M45%